

Cover Story
Real-world Evidence
By Matthew Bin Han Ong
Routine screening procedures for breast, colon, and cervical cancers in the first half of 2021 have failed to recover, falling by about a third below historical baselines, even as Americans are resuming normal activities.
In Brief


Clinical Roundup


Drugs & Targets
Trending Stories
- GRAIL to use new study results to seek FDA approval of Galleri MCD test
- Duke brain cancer researcher Kyle Walsh named director of NIEHS
- Trump cuts IVF drug deal with Merck in exchange for tariff exemption
- Science advocates organize march in DC to demand impeachment of RFK Jr.
- Friends study points to ctDNA’s potential to serve as an intermediate endpoint in NSCLC
ctMoniTR project aims to improve efficiency in development of intermediate endpoints - Revolution Medicines’ pancreatic cancer drug received a new priority voucher from FDA















